SE OF RIFAXIMIN THERAPY IN PRIMARY PREVENTION OF HEPATORENAL SYNDROME IN CIRRHOTIC PATIENTS WITH ASCITES
Not Applicable
Recruiting
- Conditions
- iver Cirrhosis with ascites
- Registration Number
- JPRN-UMIN000038487
- Lead Sponsor
- ationalAcademy of health Sciences,Bir Hospital Department Of Medicine Gastroenterology Unit
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 94
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients with renal impairment (serum creatinine>1.5mg/dl) 2. History of HRS, nephropathy and obstructive Uropathy 3. Recent exposure to radioactive materials and Nephrotoxic drugs 4. Sepsis 5. Hepatocellular carcinoma 6. History of allergic reaction with rifaxmin.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Occurrence of hepatorenal syndrome within 12 weeks.
- Secondary Outcome Measures
Name Time Method Change in urea and creatinine level at 4 week,8week and 12 week.